OIRA Conclusion of EO 12866 Regulatory Review

RIN: 0906-AB12         View EO 12866 Meetings	Received Date: 10/06/2017
Title: 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation
Agency/Subagency: HHS / HRSA
Concluded Action: Withdrawn	Concluded Date: 04/30/2018
Publication Date:
Regulatory Flexibility Analysis Required: No	Small Entities Affected:
Federalism Implications: No	Affordable Care Act [Pub. L. 111-148 & 111-152]: Yes
International Impacts: No	Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No
Pandemic Response: Uncollected